Center Laboratories Yönetim

Yönetim kriter kontrolleri 1/4

Center Laboratories CEO'su Su-Chi Wang, Oct2023 tarihinde atandı, in görev süresi 1.08 yıldır. şirketin hisselerinin 0.18% doğrudan sahiptir ve bu hisselerin değeri NT$ 64.45M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.9 yıl ve 2.8 yıldır.

Anahtar bilgiler

Su-Chi Wang

İcra Kurulu Başkanı

NT$4.7m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.1yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.9yrs
Yönetim Kurulu ortalama görev süresi	2.8yrs

Son yönetim güncellemeleri

Recent updates

We're Not Counting On Center Laboratories (GTSM:4123) To Sustain Its Statutory Profitability

Nov 20

CEO

Su-Chi Wang

1.1yrs

Görev süresi

NT$4,722,000

Tazminat

Ms. Su-Chi Wang is Chairman of Lumosa Therapeutics Co. Ltd. from May 14, 2024. Ms. Wang Serves as Chief Executive Officer, Operations Management Office & Investment Office at Center Laboratories, Inc. sinc...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Su-Chi Wang	CEO, Chief Investment Officer	1.1yrs	NT$4.72m	0.18% NT$ 64.4m
Min-Li Lien	Assistant Vice President of Legal Affairs Department	1.8yrs	NT$2.30m	Veri yok
Jui-Pao Hsu	General President of Pharmaceutical Business	1.1yrs	NT$3.47m	0.68% NT$ 243.8m
Ching-Yu Tang	Head of Corporate Governance	no data	NT$1.87m	Veri yok
Chiun-Yu Lin	Plant Director	7.8yrs	NT$2.28m	Veri yok
An-Ni Mao	Manager of Finance & Accounting Department	1.9yrs	Veri yok	Veri yok
Hsiu Yueh Lin	Director of Administration Department	26.3yrs	Veri yok	Veri yok

1.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 4123 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Su-Chi Wang	CEO, Chief Investment Officer	2yrs	NT$4.72m	0.18% NT$ 64.4m
Mei-Yueh Ho	Independent Director	4.4yrs	NT$735.00k	Veri yok
Chun-Hong Chen	Director	4.4yrs	NT$55.00k	Veri yok
Bo Zhi Zhang	Director	2.8yrs	Veri yok	0.29% NT$ 104.5m
Jialing Lin	Director	2.8yrs	Veri yok	0.71% NT$ 255.8m
Chang-Hai Tsai	Director	2.5yrs	NT$55.00k	Veri yok
Pei zhen Cai	Director	2.8yrs	Veri yok	Veri yok
Shi Jun He	Independent Director	2.8yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: 4123 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Center Laboratories Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Center Laboratories, Inc. Announces the Resignation of Lin Shirley Yi-Hsien as Independent Director

Center Laboratories, Inc., Annual General Meeting, Jun 25, 2024

Center Laboratories, Inc. Announces Executive Appointments

Center Laboratories, Inc. Announces Management Changes

Less than half of directors are independent

Center Laboratories, Inc. Elects Directors

Recent updates

Second quarter 2024 earnings released: NT$0.10 loss per share (vs NT$1.43 loss in 2Q 2023)

Center Laboratories, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Upcoming dividend of NT$1.43 per share

First quarter 2024 earnings released: NT$0.78 loss per share (vs NT$1.52 profit in 1Q 2023)

Center Laboratories, Inc. Announces the Resignation of Lin Shirley Yi-Hsien as Independent Director

Center Laboratories, Inc. to Report Q1, 2024 Results on May 13, 2024

Center Laboratories, Inc., Annual General Meeting, Jun 25, 2024

Full year 2023 earnings released: NT$1.50 loss per share (vs NT$0.16 profit in FY 2022)

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: NT$1.49 loss per share (vs NT$1.68 loss in 3Q 2022)

Upcoming dividend of NT$0.99 per share at 1.9% yield

Second quarter 2023 earnings released: NT$1.57 loss per share (vs NT$0.31 loss in 2Q 2022)

Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2022, Payable on October 13, 2023

Full year 2022 earnings released: EPS: NT$0.17 (vs NT$3.14 in FY 2021)

Center Laboratories, Inc. Announces Executive Appointments

Center Laboratories, Inc. Announces Management Changes

Less than half of directors are independent

Upcoming dividend of NT$2.43 per share

Second quarter 2022 earnings released: NT$0.36 loss per share (vs NT$2.42 profit in 2Q 2021)

Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2021

Center Laboratories, Inc. Elects Directors

First quarter 2022 earnings released: EPS: NT$2.69 (vs NT$4.21 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$3.60 (vs NT$7.73 in FY 2020)

Center Laboratories, Inc., Annual General Meeting, May 20, 2022

Third quarter 2021 earnings released: NT$1.61 loss per share (vs NT$1.90 profit in 3Q 2020)

Upcoming dividend of NT$1.50 per share

Second quarter 2021 earnings released: EPS NT$2.66 (vs NT$2.88 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$4.63 (vs NT$0.48 in 1Q 2020)

Full year 2020 earnings released: EPS NT$8.50 (vs NT$0.68 loss in FY 2019)

Center Laboratories, Inc., Annual General Meeting, May 28, 2021

New 90-day low: NT$61.90

New 90-day high: NT$72.20

We're Not Counting On Center Laboratories (GTSM:4123) To Sustain Its Statutory Profitability

Third quarter 2020 earnings released: EPS NT$2.09

New 90-day low: NT$65.20

New 90-day low: NT$68.70

First half earnings released

Upcoming Dividend of NT$1.43 Per Share

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi